CSChristopher John Sayed

Christopher John Sayed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher John Sayed has a total of 412 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Insights from HS PROGRESS, a longitudinal registry of patients with Hidradenitis Suppurativa

    by Valdemar Wendelboe Nielsen, Michelle A. Lowes, Ashley Yates, Afsaneh Alavi, R. Hal Flowers, Iltefat Hamzavi, Kristen E. Holland, Joslyn Kirby, Robert Micheletti, Gretchen M. Roth, et al.

  • Open Access

    Exposome Versus Genome in HS: How Do We Currently Explain Where Disease Arises from?

    by Emily G. Summers, Olivia D. Perez, Christopher J. Sayed, Lynn Petukhova

    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with marked clinical heterogeneity and a multifactorial pathogenesis. Environmental and lifestyle factors, including obesity, tobacco exposure, microbiome dysbiosis, dietary patterns, and plastic-associated endocrine disruptors, have all been linked to HS risk or disease severity. However, these exposures alone do not fully explain why only some individuals develop HS, why age at onset and severity vary substantially, or why disease occurs in patients without major identifiable environmental burden. In parallel, genetic studies have demonstrated that inherited susceptibility is a central component of HS pathogenesis. Rare loss-of-function variants in γ-secretase complex genes cause a small subset of familial, autosomal dominant HS, while genome-wide association studies have shown that population-level risk implicates pathways involved in epithelial differentiation, follicular biology, immune signaling, and cutaneous inflammation. Recent work further suggests that common and rare genetic risk may converge on shared biological mechanisms, including γ-secretase-related signaling. While nature vs. nurture arguments dichotomize genetic constitution and environmental exposures, current evidence supports a model in which genetic susceptibility interacts with environmental exposures to shape HS risk, clinical expression, and disease progression. In this review, we examine the evidence supporting both exposomic and genomic contributions to HS and argue that the disease is best understood as arising from their intersection rather than from either domain alone.

  • Open Access

    Educational Case: Hidradenitis suppurativa

    by Ryan C. Saal, Linnea Lackstrom Westerkam, Cristo A. Carrasco Mendoza, Paul B. Googe, Christopher J. Sayed

  • Open Access

    Patients’ Preferences for Surgical Procedures in Hidradenitis Suppurativa: A Discrete Choice Experiment

    by Katja C. Heinz, Emily G. Summers, Charlotte Beaudart, Teja Mallela, Stephanie Goldberg, Melonie Brown, Keven M. Brown, Christopher John Sayed, Mickael Hiligsmann

    Hidradenitis suppurativa is a burdensome chronic inflammatory skin disorder. While surgery can be essential for many patients, preferences and values regarding surgery are insufficiently characterized. This study aimed to investigate preferences of adult patients with hidradenitis suppurativa in the USA when choosing an hidradenitis suppurativa surgery method. A discrete choice experiment was conducted. Patients were asked to choose between two hypothetical procedures 15 times. Literature review and patients with hidradenitis suppurativa and expert interviews informed treatment attributes selection. A mixed logit model was applied to estimate preference coefficients. Subgroup analyses and a latent class model were conducted. Relevant attributes for the 205 participants (90% female, aged 41 years) ranked as follows: effectiveness on lesion improvement (36.75%), recurrence/persistence risk (15.02%), out-of-pocket costs (13.27%), post-surgical wound care (13.27%), post-surgical pain duration (9.64%), recovery time (7.12%) and complications risk (4.94%). A latent class model revealed participants in class 1 including more people of White/Caucasian, Asian and Latino ethnicity and full-time and part-time employed and non-working people put a higher value on risk of return and less priority on wound care post-surgery and out-of-pocket costs. For participants of class 2 consisting of more people of Black or other ethnicity and self-employed, students or retired people, the opposite was observed. Of the evaluated attributes, effectiveness for improvement, recurrence risk, out-of-pocket costs and post-surgical wound care contributed most to patient preference. Surgeons should account for these aspects of procedures when offering surgical interventions. Studies of surgical outcomes should place high value on these aspects of procedural outcomes.

  • Open Access

    A Genome-Wide Association Study of Hidradenitis Suppurativa from the VA’s Million Veteran Program

    by Zachary D. Wendland, Craig C. Teerlink, Kathryn M. Pridgen, Sydney Lo, Christopher Sayed, Kelsey R. van Straalen, Catherine Tcheandjieu, Philip S. Tsao, Kyong-Mi Chang, Yun Li, et al.

    Introduction: Data from family and twin studies as well as prior genome-wide association meta-analyses suggest that hidradenitis suppurativa (HS) has a hereditary component. This GWAS identifies genetic variants associated with HS. Methods: Individuals with a diagnosis of HS (defined as at least one instance of ICD9 705.83 or ICD10 L73.2) were identified within the Million Veteran Program. Multi-population and population-specific (African, European, and Hispanic ancestries) case-control genome-wide association studies (GWAS) were performed. Lead single-nucleotide polymorphisms were investigated in external resources providing phenome-wide associations (PheWAS), including UK Biobank, HugeAMP, and FinnGen. Demographic and clinical data for cases and controls were taken from the Corporate Data Warehouse and differences between the cases and control group were analyzed. Results: A total of 4,959 participants with HS were identified among 597,819 MVP participants. The multi-population GWAS identified two significant (p < 5 × 10−8) loci associated with HS, including a novel HS-related variant on chromosome 6 near HLA-DRB1 (lead variant rs679242), and confirmed a previously identified locus on chromosome 17 near SOX9 (rs55811634). The following previously identified loci associated with HS achieved suggestive evidence for association (p < 1 x 10−3): rs17090189 (13q22.1; near KLF5), rs10816701 (9q31.3; near KLF4), rs121908120 (2q35; WNT10A), and rs17103088 (14q24.3; near TMED10). Conclusion: The analysis of the MVP resource for HS identified a novel signal on chromosome 6 near HLA-DRB1 and identified significant evidence and suggestive evidence for several previously reported signals for HS.


  • Open Access

    The role of surgery in hidradenitis suppurativa: expert-based holistic approaches

    by Philippe Guillem, Christopher J Sayed, Stephanie R Goldberg, Elisa Muscianisi, Angela Llobet Martinez, Nicolas Thomas, Ivette Alarcon, Hessel H van der Zee, Falk G Bechara

    Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease characterized by painful nodules and tunnels, which are predominantly found in intertriginous skin areas such as the axillary, inguinal and anogenital regions. The condition significantly impacts patients’ quality of life owing to its chronicity and debilitating nature. While a combined medical and surgical approach is recommended for severe cases, misconceptions exist regarding the role and timing of surgery for HS, often influenced by patient fear and hesitation. A comprehensive, multidisciplinary approach involving a multimodal therapeutic strategy is essential for successful HS outcomes. The decision to opt for surgery depends on various factors such as disease severity, lesion characteristics, anatomical location and patient preferences. Although surgery remains a cornerstone in managing recurrent and severe cases of HS, surgical interventions, when combined with targeted medical therapies, can lead to favourable outcomes and improved disease control. This review aims to guide clinicians in decision making around the suitability of surgery by providing a framework for surgery in HS in the context of various clinical scenarios.


  • Open Access

    Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

    by Christopher J. Sayed, Brian Kirby, Amit Garg, Haley B. Naik, Alexa B. Kimball, Christos C. Zouboulis, Gregor B.E. Jemec, Georgios Kokolakis, John R. Ingram, Akimichi Morita, et al.


  • Open Access

    Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial

    by Evangelos J Giamarellos-Bourboulis, Gregor B E Jemec, Errol P Prens, Niels C Riedemann, Isabell Otto, Jamie Weisman, Grazyna Pulka, Roman J Nowicki, Vessel Kantardjiev, Andreas Pinter, et al.

    Background: The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment. Objectives: To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS. Methods: In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276). Results: The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40. Conclusions: Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.


  • Open Access

    Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa

    by K Alaine Broadaway, Quan Sun, Sharon N Edmiston, Kevin W Currin, Swarooparani Vadlamudi, Tyne W Miller-Fleming, Yue Shi, Kristen Fajgenbaum, Maria Melendez-Gonzalez, Helen Bui, et al.

    Background: Hidradenitis suppurativa (HS) is a common, chronic and debilitating inflammatory disease that most commonly affects intertriginous skin. Despite its high heritability, the genetic underpinnings of HS remain poorly understood. Objectives: To identify genetic signals associated with HS, determine genetic relationships with other diseases and investigate potential molecular genetic mechanisms. Methods: We performed a genome-wide association meta-analysis of six studies, totalling 4540 patients with HS and > 1 million control participants, and identified genetic correlations with other common diseases. We integrated the HS data with expression quantitative trait loci from 10 trait-relevant tissues, epigenomic and transcriptomic data from human scalp, differential expression data from HS lesions vs. adjacent skin and mesenchymal Hi-C chromatin looping data. To identify functional noncoding variants, we performed transcriptional reporter assays for signals near KLF5 and SOX9. Results: We identified 11 significant HS signals across 7 loci: 4 corresponded to previously reported associations, 4 represented novel signals within known loci and 3 were signals in newly implicated loci. We identified significant genetic correlations between HS and other inflammatory conditions, particularly inflammatory bowel disease, rheumatoid arthritis, type 2 diabetes mellitus and asthma. We prioritized candidate genes for the 11 signals. The risk allele at KLF5 exhibited 10-fold greater transcriptional activity than the nonrisk allele, while risk alleles at SOX9 showed significantly reduced transcriptional activity. Conclusions: Our results provide insights into potential genetic mechanisms underlying HS and suggest potential therapeutic targets for this challenging condition.


  • Open Access

    Associations of Hidradenitis Suppurativa with Atopic Dermatitis: A Review of Shared Pathogenesis and Approach to Treatment of Concomitant Disease

    by Rayad B. Shams, Hiral S. Patel, Christopher J. Sayed

    Hidradenitis suppurativa (HS) and atopic dermatitis (AD) are both inflammatory dermatoses that can significantly impact patient quality of life, however, limited research exists regarding their association. The purpose of this comprehensive review is to compare the inflammatory pathogenesis of HS and AD, explore the associations between these diseases, and discuss standalone and concomitant disease treatment options. Although HS and AD are understood to be primarily driven by the Th1 and Th2 inflammation pathways, respectively, these conditions both utilize the Janus Kinase/Signal transducer and activator of transcription (JAK/STAT) pathway to promote inflammation. Newer research also suggests that IL-36 and IL-1 receptor-associated kinase 4 (IRAK4) may be two additional inflammatory signals shared between the HS and AD disease pathways. These shared mechanisms are reflected in patient presentations as HS and AD are often concomitantly present and demonstrate a bidirectional association in the current literature. Treatment options for concomitant disease are limited, but leverage the shared immune pathogenesis of both diseases. Dupilumab has been reported to improve both HS and AD symptoms in select patients. JAK inhibitors are currently FDA-approved for the treatment of AD, and early trials have suggested benefits from JAK inhibitors such as upadacitinib, povorcitinib, and topical ruxolitinib for HS. Possible future avenues for research on treating both HS and AD include IRAK-4 inhibitors such as zabedosertib and BAY1830839, and diet and gut microbiome modifications.